Blog
RSS FeedPosted by Michael Wonder on 12 Oct 2016
Decision to award sole supply of venlafaxine
12 October 2016 - PHARMAC is pleased to announce a decision to award a sole supply arrangement for venlafaxine hydrochloride ...
Posted by Michael Wonder on 12 Oct 2016
CADTH calls for patient input on submission from Servier for Corlovan
11 October - CADTH is calling for patient input on a submission from Servier for Corlovan (ivabradine hydrochloride). ...
Posted by Michael Wonder on 12 Oct 2016
PBAC Guidelines
12 October 2016 - The PBAC has endorsed version 5.0 of their guidelines. ...
Posted by Michael Wonder on 11 Oct 2016
Breast cancer chemotherapy costs vary despite similar effectiveness
11 October 2016 - Chemotherapy regimens for breast cancer can vary wildly in price even when they are comparable in ...
Posted by Michael Wonder on 11 Oct 2016
Cost, effectiveness, and value. How to judge?
11 October 2016 - Former NICE Chairman Sir Michael Rawlins offers his views in JAMA. ...
Posted by Michael Wonder on 11 Oct 2016
NICE publishes draft guidance on the use of Otezla on the NHS
11 October 2016 - NICE has published draft guidance on the use of Otelza (apremilast) on the NHS by patients ...
Posted by Michael Wonder on 11 Oct 2016
Cutting through the numbers on health-care funding
11 October 2016 - One of the truisms of Canadian political discourse is that the federal government grossly underfunds health ...
Posted by Michael Wonder on 11 Oct 2016
Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals
7 October 2016 - Academic researchers from the UK have assessed the adequacy of reporting of non-inferiority trials alongside the ...
Posted by Michael Wonder on 11 Oct 2016
People with an advanced form of thyroid cancer now able to benefit from Lenvima (lenvatinib mesylate) in Scotland
10 October 2016 - Patients in England denied access to lenvatinib mesylate due to administrative delays. ...
Posted by Michael Wonder on 11 Oct 2016
Multi-product proposal involving nine pharmaceuticals
11 October 2016 - PHARMAC is seeking feedback on a proposal to fund three new treatments, widen access to three ...
Posted by Michael Wonder on 11 Oct 2016
Decision regarding funding of the HIV treatments dolutegravir (Tivicay) and abacavir sulphate with lamivudine (Kivexa)
11 October 2016 - PHARMAC is pleased to announce that the approval of an agreement with GlaxoSmithKline for the funding ...
Posted by Michael Wonder on 11 Oct 2016
A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK
11 October 2016 - Drug listing recommendations from health technology assessment agencies often fail to coincide with one another. ...
Posted by Michael Wonder on 10 Oct 2016
Health and aged care are the new productivity reform frontier, Parkinson says
10 October 2016 - Australia needs to improve the productivity of its health and aged care sectors if it is ...
Posted by Michael Wonder on 10 Oct 2016
Life-extending lung cancer drug approved for use in Scotland
10 October 2016 - Scotland has become the first part of the UK to approve a new life-extending treatment for ...
Posted by Michael Wonder on 10 Oct 2016
SMC - October 2016 decisions
10 October 2016 - New treatments for thyroid cancer and lung cancer among five medicines accepted for routine use by ...